Indonesia: analgesics market revenue 2029

The revenue in the 'Analgesics' segment of the otc pharmaceuticals market in Indonesia was forecast to continuously increase between 2024 and 2029 by in total 312 million U.S. dollars (+54.23 percent). After the ninth consecutive increasing year, the revenue is estimated to reach 887.29 million U.S. dollars and therefore a new peak in 2029. Notably, the revenue of the 'Analgesics' segment of the otc pharmaceuticals market was continuously increasing over the past years.

Find further information concerning the revenue change in the 'Vitamins & Minerals' segment of the otc pharmaceuticals market in the Philippines and the revenue in the 'Digestives & Intestinal Remedies' segment of the otc pharmaceuticals market in Singapore.

The Statista Market Insights cover a broad range of additional markets.

Revenue of the analgesics market in Indonesia from 2020 to 2029 (in million U.S. dollars)

Characteristic	Revenue in million U.S. dollars
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

Definition:
The Analgesics market comprises over-the-counter natural and synthetic non-opioid analgesics (only in approved low doses) like Paracetamol, Ibuprofen, Aspirin, Diclofenac and other pain-relieving preparations. Legislation on opioid analgesics differs from country to country. According to the respective state legislation, legal opioid analgesics are included. In Germany, Austria and Switzerland, for instance, opioid analgesics are only included if they are not limited by the narcotics law and do not require prescription. Analgesics are included in the form of pills, capsules, gels and ointments. Not included are prescription medicines (e.g. morphine), anesthetics and homeopathic remedies. Among the top-selling painkillers are Voltaren, Aspirin, Thomapyrin, Ibuprofen, Dolormin, Paracetamol and ASS. It includes both products which are exclusively sold in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Additional information:
The Analgesics market comprises revenues, average revenue per capita. Sales channels show online and offline revenue. Revenues include VAT. The market only displays B2C revenues, hence B2B and B2G revenues are not included.
For more information on the data displayed, use the info button next to the boxes.

Citation formats